Pozelimab and Cemdisiran in PNH: Efficacy and Safety in a Phase 3 Study

24 Feb 20267 min read0 viewsINTERVENTIONAL Trial

GIST

Official title: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy Summary: This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH).

The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab. The pozelimab + cemdisiran combination may be referred to as "study drugs".

Ravulizumab and eculizumab may also be called the "comparator drug". The study is looking at several research questions, including: * How effective is the pozelimab + cemdisiran combination compared to ravulizumab?

* How effective is pozelimab + cemdisiran combination compared to eculizumab? * What side effects may happen from taking the study drugs?

* How much study drugs are in the blood at different times?

Clinical Editorial

Study Design and Purpose Inference

A randomized, open-label, C5 inhibitor–controlled study investigates the safety and efficacy of a pozelimab and cemdisiran combination in adults with PNH who are naive to complement inhibitors or have recently not received such therapy.
The trial compares the experimental combination with two established C5 inhibitors, ravulizumab and eculizumab, to determine relative efficacy and safety.

Population and Intervention Details

Population: Adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH), without recent complement inhibitor exposure or treatment-naive to complement inhibitors.
Intervention: A combination regimen using pozelimab plus cemdisiran described as the study drugs.
Comparators: Ravulizumab and eculizumab, referred to as the comparator drugs in the protocol.

Research Questions and Outcomes

Primary inquiries center on comparative effectiveness: pozelimab plus cemdisiran versus ravulizumab, and versus eculizumab.
Secondary or exploratory questions include the safety profile, occurrence of adverse events, pharmacokinetic measures (drug levels over time), and immunogenicity (antibody formation against study drugs).

Study Characteristics and Status

Design features include randomization and open-label administration with active comparator arms.
Primary purpose is treatment-related, targeting disease management in PNH.
Phase: 3, indicating late-stage evaluation.
Enrollment target is 190 participants (estimated).
Current status is recruiting, with an estimated completion date of January 28, 2027 (EST).

Limitations and Gaps Protecting Context

The provided content does not report specific endpoints, numerical results, or detailed safety signals.
It does not specify inclusion/exclusion criteria beyond prior exposure status, nor does it present interim data or subgroup analyses.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT05133531

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Specialty

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Oncology • 20 May 2026

Br J CancerRelated by Specialty

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

Nat Rev OncRelated by Specialty

Source

ClinicalTrials.gov